Nektar Therapeutics Class Action Lawsuit Over REZOLVE-AA Trial
Analysis based on 134 articles · First reported Mar 06, 2026 · Last updated Apr 16, 2026
The class action lawsuit against Nektar Therapeutics, stemming from alleged misrepresentations about its REZOLVE-AA trial, has negatively impacted Nektar Therapeutics' stock price. This event highlights the risks associated with clinical trial integrity and corporate disclosures, potentially leading to increased scrutiny on biopharmaceutical companies' trial protocols and public statements.
A class action lawsuit has been filed against Nektar Therapeutics by Pomerantz LLP and The Rosen Law Firm on behalf of investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025. The lawsuit alleges that Nektar Therapeutics made materially false and misleading statements regarding its Phase 2b REZOLVE-AA trial for rezpegaldesleukin, a treatment for alopecia areata. Specifically, it claims that enrollment in the trial did not follow applicable instructions and protocol standards, which negatively impacted the trial's results and overstated its integrity and prospects. The truth emerged on December 16, 2025, when Nektar Therapeutics announced that the trial failed to reach statistical significance, attributing it to the inclusion of ineligible patients. This news caused Nektar Therapeutics' stock price to fall significantly.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard